5-HT2C receptor modulation and the treatment of obesity

Diabetes, Obesity and Metabolism

Volumn 1, Issue 4, 1999, Pages 207-214

  Bickerdike, Mike J ^a   Vickers, Steven P ^a   Dourish, Colin T ^a  

^a Cerebrus Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; FENFLURAMINE; SEROTONIN 2C RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANIMAL; DISEASE MODEL; DRUG EFFECT; HUMAN; OBESITY; PHYSIOLOGY; REVIEW;

ANIMALS; APPETITE DEPRESSANTS; CYCLOBUTANES; DISEASE MODELS, ANIMAL; FENFLURAMINE; HUMANS; OBESITY; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0033157213     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00037.x     Document Type: Review

References (77)

1. Bennett N, Dodd T, Flatley J, Freeth S, Bolling K. Health Survey for England 1993. London: HMSO, 1995.
2. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys 1960-91. J Am Med Assoc 1994; 272: 205-211.
3. Bray GA. Obesity: a time bomb to be defused. Lancet 1998; 352: 160-161.
4. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97-106.
5. Noble RE. Effect of cyproheptadine on appetite and weight gain in adults. J Am Med Assoc 1969; 209: 2054-2055.
6. Latham CJ, Blundell JE. Evidence for the effect of tryptophan on the pattern of food consumption in rats. Life Sci 1979; 24: 1271-1278.
7. Saller CF, Stricker EM. Hyperphagia and increased growth in rats after intraventricular injection of 5,7-dihydroxytryptamine. Science 1976; 192: 385-387.
8. Waldbillig RJ, Bartness TJ, Stanley BG. Increased food intake, body weight, and adiposity in rats after regional neurochemical depletion of serotonin. J Comp Physiol Psychol 1981; 95: 391-405.
9. Coscina DV. Effects of central 5,7-dihydroxytryptamine on the medial hypothalamic syndrome in rats. Ann NY Acad Sci 1978; 305: 627-644.
10. Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977; 1: 15-42.
11. Dourish CT. Multiple serotonin receptors: opportunities for new treatments for obesity. Obes Res 1995; 3 (Suppl): 449S-462S.
12. Dourish CT, Hutson PH, Curzon G. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino] tetralin (8-OH-DPAT] elicit feeding in the rat. Psychopharmacology 1985; 86: 197-204.
13. 2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 1997; 36: 233-239.
14. 1B agonists induce anorexia at postsynaptic site. Eur J Pharmacol 1987; 141: 429-435.
15. 1B receptors. Psychopharmacology 1988; 96: 93-100.
16. Conn CJ, Sanders-Bush E, Hoffman BJ, Hartig PR. A unique serotonin receptor in choroid plexus is linked to phospatidylinositol turnover. Proceed Nat Acad Sci USA 1986; 83: 4086-4088.
17. Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterisation of a new type of serotonin recognition site. Eur J Pharmacol 1984; 106: 539-546.
18. 1C receptor. Ann NY Acad Sci 1990; 600: 149-167.
19. 1C receptor mRNA in adult rat brain. FEBS Letts 1989; 247: 453-462.
20. 1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proceed Nat Acad Sci USA 1989; 86: 6793-6797.
21. 1C receptors and their therapeutic relevance. Curr Op Invest Drugs 1993; 2: 317-362.
22. Conn PJ, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Experiment Ther 1987; 242: 552-557.
23. Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S. m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn-Schmiedeberg's Arch Pharm 1979; 308: 159-163.
24. Fuller RW, Snoddy HD, Mason NR, Hemrick-Luecke SK, Clemens JA. Substituted piperazines as central serotonin agonists: comparative specificity of the postsynaptic actions of quipazine and m-trifluoromethylphenyl-piperazine. J Pharmacol Experiment Ther 1981; 218: 636-641.
25. 1C receptors. Br J Pharmacol 1988; 94: 137-147.
26. Klodzinska A, Chojnacka-Wojcik E. Anorexia induced by m-trifluoromethylphenyl piperazine (TFMPP) in rats. Pol J Pharmacol Pharm 1990; 42: 13-17.
27. 1C receptors mediate 1-3 (chlorophenyl) piperazine-induced hypophagia. Br J Pharmacol 1991; 103: 2016-2020.
28. 2C/2B receptor antagonist. Br J Pharmacol 1994; 111: 797-802.
29. Schechter LE, Simansky KJ. 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorectic action that is blocked by 5-HT2 antagonists in rats. Psychopharmacology 1988; 94: 342-346.
30. Vaupel DB, Morton EC. Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacol Biochem Behavior 1982; 17: 539-545.
31. 2C receptors, respectively. Neuropsychopharmacology 1995; 13: 1-8.
32. 1C and 5-HT2 receptor agonists using the post-prandial satiety sequence in rats. Psychopharmacology 1994; 113: 369-377.
33. Halford JCG, Wanninyate SCD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behavior 1998; 61: 159-168.
34. Lucki I, Ward HR, Frazer A. Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl) piperazine on locomotor acitivity. J Pharmacol Experiment Ther 1989; 249: 155-164.
35. Halford JCG, Lawton CL, Blundell JE. The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence. Pharmacol Biochem Behavior 1997; 56: 41-46.
36. Lawton CL, Blundell JE. 5-HT manipulation and dietary choice: variable carbohydrate (polycose) suppression demonstrated only under specific experimental conditions. Psychopharmacology 1993; 112: 375-382.
37. Walsh AES, Smith KA, Oldman AD, Williams C, Goodall EM, Cowen PJ. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 1994; 116: 120-122.
38. 2c receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Experiment Ther 1998; 286: 913-924.
39. 2C receptor agonist Ro 60-0175 decreases meal size and accelerates the onset of the behavioural satiety sequence in the rat. Soc Neurosci 1998; 24: 406.5.
40. 2c receptor antagonist. Neuropharmacology 1997; 36: 609-620.
41. 2C receptors and ingestive behaviour in mice. J Psychopharmacol 1998; 12: A38.
42. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology 1993; 113: 262-268.
43. Rouru J, Pesonen U, Isaksson K, Huupponen R, Koulu M. Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats. Eur J Pharmacol 1993; 234: 191-198.
44. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 1997; 133: 309-312.
45. Rowland NE, Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol 1986; 27: 13-62.
46. 2c receptor levels in the rat. Br J Pharmacol 1998; 123: 1707-1715.
47. Plata-Salaman CR. Hypothalamus and the control of feeding: fifteen decades of direct association. Nutrition 1998; 14: 67-70.
48. Schwartz DH, McClane S, Hernandez L, Hoebel BG. Feeding increases extracellular serotonin in the lateral hypothalamus of the rat as measured by microdialysis. Brain Res 1989; 479: 349-354.
49. Schwartz DH, Hernandez L, Hoebel BG. Serotonin release in lateral and medial hypothalamus during feeding and its anticipation. Brain Res Bull 1990; 25: 797-802.
50. Wang Q, Bing C, Al-Barazanji K et al. Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes 1997; 46: 335-341.
51. Hutson PH, Donohoe TP, Curzon GC. Infusion of the 5-hydroxytryptamine agonists RU 24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia. Psychopharmacology 1988; 95: 550-552.
52. Fletcher PJ, Ming ZH, Zack MH, Coscina DV. A comparison of the effects of the 5-HT agonists TFMPP and RU 24969 on feeding following peripheral or medial hypothalamic injection. Brain Res 1992; 580: 265-272.
53. Kaplan JM, Song S, Grill HJ. Serotonin receptors in the caudal brainstem are necessary and sufficient for the anorectic effect of peripherally administered mCPP. Psychopharmacology 1998; 137: 43-49.
54. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. New Engl J Med 1997; 337: 581-588.
55. Khan MA, Herzog CA, St Peter JV et al. The prevelence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. New Engl J Med 1998; 339: 713-718.
56. Blundell JE, Latham CJ. Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism produced by pimozide and metergoline. Pharmacol Biochem Behavior 1980; 12: 717-722.
57. 1A receptor. Psychopharmacology 1996; 125: 168-175.
58. Grignaschi G, Samanin R. Role of 5-HT receptors in the effect of d-fenfluramine on feeding patterns in the rat. Eur J Pharmacol 1992; 212: 287-289.
59. 2c receptors in mediating fenfluramine-induced anorexia in rats. Br J Pharmacol 1995; 114: 373P.
60. 1B receptor ligands on appetite control in the rat. Br J Pharmacol 1998; 123: 238P.
61. Neill JC, Cooper SJ. Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology 1989; 97: 213-218.
62. Rosenzweig-Lipson S, Kelly MG, Abrol S, Finn M, Sukoff SJ. Modification of the behavioural effects of d-fenfluramine and mCPP by SB-200646 in rats and monkeys. Soc Neurosci 1997; 23: 102.28.
63. Mennini T, Bizzi A, Caccia S et al. Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs. Naunyn-Schmeideberg's Arch Pharmacol 1991; 343: 483-490.
64. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1997; 18: 21-25.
65. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124.
66. Jackson HC, Bearham MC, Hutchins LJ, Mazurkiewicz SE, Needham AM, Heal DJ. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613-1618.
67. 2c receptors. Nature 1995; 374: 542-546.
68. 2c receptor gene. Nature Med 1998; 4: 1151-1156.
69. 2c receptor mutant mice. Psychopharmacology 1999; 143: 309-314.
70. Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R. Absence of fenfluramine-induced anorexia and reduced c-fos induction in the hypothalamus and central amygdaloid complex of serotonin IB receptor knock-out mice. J Neurosci 1998; 18: 5537-5544.
71. Fletcher PJ. Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin. Psychopharmacology 1988; 96: 237-242.
72. Dourish CT, Clark ML, Fletcher A, Iversen S. Evidence that blockade of post synaptic 5-HT1 receptors elicits feeding in satiated rats. Pyschopharmacology 1989; 97: 54-58.
73. 2c receptor antagonist. Neuropharmacology 1997; 36: 621-629.
74. Guy-Grand B. Clinical studies with d-fenfluramine. Am J Clin Nutr 1992; 55 (1 (Suppl.): 173S-176S.
75. Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 1993; 112: 461-466.
76. Caccia S, Ballabio M, Samanin R, Zanini MG, Garattini S. mCPP, a central 5-HT agonist, is a metabolite of trazodone. J Pharm Pharmacol 1981; 33: 477-478.
77. 1C agonists. Psychopharmacology 1988; 96: 101-103.